Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis

Author:

Tiberio Paola1ORCID,Gaudio Mariangela12,Belloni Silvia3ORCID,Pindilli Sebastiano2,Benvenuti Chiara12ORCID,Jacobs Flavia12ORCID,Saltalamacchia Giuseppe1,Zambelli Alberto12ORCID,Santoro Armando12ORCID,De Sanctis Rita12ORCID

Affiliation:

1. Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy

2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy

3. Educational and Research Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy

Abstract

The potential role of circulating microRNAs (miRNAs) as biomarkers in breast cancer (BC) management has been widely reported. However, the numerous discrepancies between studies in this regard hinders the implementation of circulating miRNAs in routine clinical practice. In the context of BC patients undergoing neoadjuvant chemotherapy (NAC), the possibility of predicting NAC response may lead to prognostic improvements by individualizing post-neoadjuvant therapy. In this context, the present meta-analysis aims to clarify circulating miRNAs’ predictive role with respect to NAC response among BC patients. We conducted a comprehensive literature search on five medical databases until 16 February 2023. We pooled the effect sizes of each study by applying a random-effects model. Cochran’s Q test (p-level of significance set at 0.05) scores and I2 values were assessed to determine between-study heterogeneity. The PROBAST (Prediction Model Risk of Bias Assessment Tool) tool was used to evaluate the selected studies’ risk of bias. Overall, our findings support the hypothesis that circulating miRNAs, specifically miR-21-5p and miR-155-5p, may act as predictive biomarkers in the neoadjuvant setting among BC patients. However, due to the limited number of studies included in this meta-analysis and the high degrees of clinical and statistical heterogeneity, further research is required to confirm the predictive power of circulating miR-21-5p and miR-155-5p.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference127 articles.

1. Breast cancer;Loibl;Lancet,2021

2. Origins of breast cancer subtypes and therapeutic implications;Sims;Nat. Clin. Pract. Oncol.,2007

3. Neoadjuvant chemotherapy for operable breast cancer;Mieog;Br. J. Surg.,2007

4. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis;Cortazar;Lancet,2014

5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials. Lancet Oncol., 19, 27–39.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3